No Data
No Data
The Three-year Decline in Earnings for Zhejiang Jingxin Pharmaceutical SZSE:002020) Isn't Encouraging, but Shareholders Are Still up 43% Over That Period
Zhejiang Jingxin Pharmaceutical (002020.SZ): 67.5676 million restricted shares will be listed for trading from September 11th.
Zhejiang Jingxin Pharmaceutical (002020.SZ) issued a notification regarding the listing and circulation of privately placed restricted shares in 2020.
Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Zhejiang Jingxin Pharmaceutical (002020.SZ): JX11502MA capsules and Kangfu Xin enteric capsules II clinical trials are underway.
On August16th, www.glinfo.com reported that on August 15th, 2024, Zhejiang Jingxin Pharmaceutical (002020.SZ) stated during a specific object investigation that clinical trials of JX11502MA capsules and KefuXin enteric-coated capsules II are underway; JX2105 capsules have received clinical trial approvals, and Phase I clinical trials are progressing smoothly; more than 10 other research projects are being carried out in an orderly manner.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's sales expenses in the first half of the year were 0.384 billion, a year-on-year decrease of 3.63%.
On August 15, 2024, zhejiang jingxin pharmaceutical (002020.SZ) stated during a specific object investigation that the company's sales expenses for the first half of 2024 were 0.384 billion, a year-on-year decrease of 3.63%, and the sales expense ratio decreased by 2.72 percentage points. The company has achieved a continuous decrease in sales expenses in recent years, partly due to the company's emphasis on improving sales efficiency; on the other hand, it stems from the adjustment of the internal structure of sales expenses, and precise cost control. With the market promotion of Daxini, it is inevitable that there will be certain expenses, but the company will strive to control the sales expense ratio, hoping to
Zhejiang Jingxin Pharmaceutical: Half-year report for the year 2024.
No Data
No Data